Avet Lifesciences Private Limited

Avet Lifesciences Private Limited, established on August 26, 2020, is a pharmaceutical manufacturing company headquartered in Pune, Maharashtra, India. The company specializes in the formulation and development of finished pharmaceutical products, including tablets, capsules, syrups, and injections. Registered under the Corporate Identification Number (CIN) U24299PN2020PTC193397, Avet Lifesciences operates as a private unlisted entity. The authorized capital stands at ₹20.00 crore, with a paid-up capital of ₹15.45 crore. As of April 4, 2024, the company employed 28 professionals.

Avet Lifesciences Private Limited's manufacturing facility is located at A-402, 4th Floor, Ganga Osian Square, Survey No. 249/250, Tal – Mulshi, Wakad, Pune, Maharashtra, 411057. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly disclosed.

The leadership team at Avet Lifesciences Private Limited includes:

• Ulhas Rajaram Puranik: Director, appointed on September 22, 2021.

• Brijmohan Sharma: Director, appointed on September 6, 2021.

• Mandar Chintaman Joshi: Company Secretary, appointed on July 17, 2023.

• Nikhil Deepak Shah: Chief Financial Officer (CFO), appointed on September 15, 2022.

Avet Lifesciences Private Limited has engaged in the export of finished pharmaceutical formulations to various international markets. Between 2022 and 2026, the company reported a total export value of $6.5 million USD across 135 shipments, encompassing three products across three therapeutic categories. The top three products exported were Amikacin ($2.4 million, 11.1% market share), Metoclopramide ($1.5 million, 6.6% market share), and Furosemide ($2.7 million, 3.8% market share). The primary therapeutic categories included Advanced Antibiotics (36.0%), Diuretics (41.1%), and Gastrointestinal (23.0%). Notably, Avet Lifesciences holds the position of the number one market leader in Amikacin. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its export value.

Avet Lifesciences Private Limited has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's focus on obtaining WHO prequalification for its products has facilitated access to these markets, enabling the distribution of high-quality pharmaceutical formulations to a broader global audience. Specific details regarding market penetration and regulatory approvals in these regions are not publicly disclosed.

Avet Lifesciences Private Limited's export strategy demonstrates a diversified approach, targeting multiple international markets to mitigate concentration risk. The company's focus on high-demand therapeutic categories such as Advanced Antibiotics, Diuretics, and Gastrointestinal products aligns with global healthcare needs. This strategic direction positions Avet Lifesciences to capitalize on growth opportunities in various regions while maintaining a balanced portfolio.

Specific details regarding Avet Lifesciences Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's export activities to the United States suggest compliance with FDA regulations; however, comprehensive information is not disclosed.

Avet Lifesciences Private Limited has pursued compliance with international Good Manufacturing Practice (GMP) standards, including those set by the World Health Organization (WHO) and the European Union (EU). Obtaining WHO prequalification for its products has enabled the company to access emerging markets. Specific details regarding EU GMP certifications and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed.

Avet Lifesciences Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) and other regulatory approvals are not publicly disclosed.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Avet Lifesciences Private Limited by regulatory authorities. The absence of such records suggests a favorable compliance history; however, comprehensive information is not disclosed.

Avet Lifesciences Private Limited operates in a competitive pharmaceutical export market, with key competitors in overlapping therapeutic categories such as Advanced Antibiotics, Diuretics, and Gastrointestinal products. While specific market share comparisons and head-to-head analyses are not publicly available, the company's focus on high-demand therapeutic areas positions it to effectively compete in these segments.

Avet Lifesciences Private Limited's key differentiators include its concentrated portfolio of high-demand pharmaceutical formulations, particularly in Advanced Antibiotics, Diuretics, and Gastrointestinal products. The company's commitment to obtaining WHO prequalification for its products enhances its credibility and facilitates access to emerging markets. Additionally, Avet Lifesciences' strategic focus on maintaining a diversified export strategy across multiple international markets mitigates concentration risk and supports sustainable growth.

Avet Lifesciences Private Limited's current strategic direction emphasizes the export of generic pharmaceutical formulations, with a strong focus on high-demand therapeutic categories. The company's pursuit of WHO prequalification and compliance with international GMP standards reflect its commitment to quality and global market access. Looking ahead, Avet Lifesciences is well-positioned to expand its presence in emerging markets and strengthen its competitive position in the global pharmaceutical industry.

Avet Lifesciences Private Limited has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $6.5 million USD across 135 shipments between 2022 and 2026. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its export value, indicating a focused and reliable supply chain. While specific reliability indicators are not publicly disclosed, the company's adherence to international GMP standards and pursuit of WHO prequalification suggest a commitment to quality and consistency in its manufacturing processes.

Importers should verify the following certifications when considering Avet Lifesciences Private Limited as a supplier:

• WHO Prequalification: Confirms that the company's products meet international quality standards, facilitating access to emerging markets.

• EU GMP Certification: Indicates compliance with European Union Good Manufacturing Practice standards, ensuring product quality and safety.

• ISO Certifications: Demonstrate adherence to international standards for quality management systems.

To verify these certifications, importers can request copies of the certificates directly from Avet Lifesciences Private Limited or consult the respective regulatory bodies' official websites for validation.

When conducting due diligence on Avet Lifesciences Private Limited, importers should consider the following steps:

• Verify Regulatory Approvals: Confirm that the company's products are approved by relevant regulatory authorities in target markets.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities for compliance with international GMP standards.

• Review Financial Stability: Analyze the company's financial statements to assess its financial health and stability.

• Check for Compliance History: Investigate any past regulatory actions, such as warning letters or import alerts, to assess compliance history.

• Evaluate Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain to ensure timely delivery of products.

Red flags to watch for include unresolved regulatory issues, financial instability, and a history of non-compliance with international standards. Recommended pre-order checks involve verifying certifications, assessing product quality, and conducting site visits to manufacturing facilities.